COVID-19 pandemic and allergen immunotherapy-an EAACI survey.

ABSTRACT:

Background

As in many fields of medical care, the coronavirus disease 2019 (COVID-19) resulted in an increased uncertainty regarding the safety of allergen immunotherapy (AIT). Therefore, the European Academy of Allergy and Clinical Immunology (EAACI) aimed to analyze the situation in different countries and to systematically collect all information available regarding tolerability and possible amendments in daily practice of sublingual AIT (SLIT), subcutaneous AIT (SCIT) for inhalant allergies and venom AIT.

Methods

Under the framework of the EAACI, a panel of experts in the field of AIT coordinated by the Immunotherapy Interest Group set-up a web-based retrospective survey (SurveyMonkey^® ) including 27 standardized questions on practical and safety aspects on AI

SUBMITTER: Pfaar O 

PROVIDER: S-EPMC8013670 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature